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Abstract
Background:	Inherited	thrombocytopenias	(ITs)	are	a	heterogeneous	group	of	disor-
ders	characterized	by	low	platelet	counts	and	often	disproportionate	bleeding	with	
over	 30	 genes	 currently	 implicated.	 Previously	 the	 UK-	GAPP	 study	 using	 whole	
exome	sequencing	(WES)	identified	a	pathogenic	variant	in	19	of	47	(40%)	patients	of	
which	71%	had	variants	in	genes	known	to	cause	IT.
Aims:	To	employ	a	 targeted	next-generation	sequencing	platform	 to	 improve	effi-
ciency	of	diagnostic	testing	and	reduce	overall	costs.
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1  | INTRODUCTION
Inherited	thrombocytopenias	(ITs)	are	a	heterogeneous	group	of	dis-
orders	characterized	by	a	sustained	reduction	in	platelet	count	often	
manifesting	as	a	bleeding	diathesis.	Since	the	discovery	of	disease	
inheritance	patterns	in	disorders	such	as	Bernard	Soulier	Syndrome	
(BSS),	genetic	studies	of	thrombocytopenia	have	been	a	vital	tool	in	
determining	megakaryocyte	and	platelet	physiology.1	As	a	result	of	
parallel	whole	exome	and	whole	genome	sequencing	over	the	past	
5-	10	years,	we	 are	 discovering	 increasing	 numbers	 of	 novel	 genes	
and	variants	with	 a	 critical	 role	 in	platelet	 production,	 physiology,	
and	function.2–5
To	 date,	 there	 are	 30	 genes	 suspected	 to	 cause	 26	 separate	
forms	of	inherited	thrombocytopenia	making	genetic	diagnosis	com-
plex.6	 However,	 until	 recently,	 IT	 remained	 underdiagnosed	 with	
previous	studies	only	providing	a	genetic	diagnosis	in	just	over	50%	
of	 individuals.7–9	 A	 genetic	 diagnosis	 provides	 clinical	 benefits	 for	
the	patients.	Some	patients	with	a	reduced	platelet	count	have	had	
unnecessary	 treatments	 and	 procedures	 such	 as	 immunosuppres-
sion	and	splenectomies	and	therefore	establishing	that	they	have	an	
inherited	component	to	their	disease	etiology	would	prevent	this.	In	
the	case	of	suspected	ITP	this	may	be	treated	with	steroids	or	immu-
nosuppressive	drugs	with	many	side	effects.	Therefore,	if	such	pa-
tients	are	proven	to	have	an	inherited	thrombocytopenia,	then	these	
treatments	are	unnecessary.	Some	of	the	gene	mutations	in	patients,	
eg,	RUNX1,	result	in	patients	having	a	predisposition	to	hematologi-
cal	malignancies	and	once	a	genetic	defect	is	proven,	the	information	
can	be	used	to	monitor	the	patients’	hematological	parameters	more	
closely.	These	all	highlight	the	need	for	a	definitive	genetic	diagnosis	
and	development	of	 a	 targeted	gene-	specific	 sequencing	platform	
will	provide	a	quick	and	cost	effective	screening	for	patients	with	IT.
As	new	sequencing	library-	capture	methods	are	developed,	the	
speed	of	 sample	 preparation	 time	 is	 vastly	 reduced.	 Thus,	 the	 re-
cently	 released	 capture	 methods,	 Illumina	 Nextera	 Rapid	 Custom	
Methods:	We	have	developed	an	IT-	specific	gene	panel	as	a	pre-	screen	for	patients	
prior	to	WES	using	the	Agilent	SureSelectQXT	transposon-	based	enrichment	system.
Results:	 Thirty-	one	 patients	 were	 analyzed	 using	 the	 panel-	based	 sequencing,	 of	
which;	10%	 (3/31)	were	 identified	with	a	 classified	pathogenic	variant,	16%	 (5/31)	
were	identified	with	a	likely	pathogenic	variant,	51%	(16/31)	were	identified	with	vari-
ants	of	unknown	significance,	and	23%	(7/31)	were	identified	with	either	no	variant	
or	a	benign	variant.
Discussion and Conclusion:	Although	requiring	further	clarification	of	the	impact	of	
the	genetic	variations,	the	application	of	an	IT-	specific	next	generation	sequencing	
panel	is	a	viable	method	of	pre-	screening	patients	for	variants	in	known	IT-	causing	
genes	prior	to	WES.	With	an	added	benefit	of	distinguishing	IT	from	idiopathic	throm-
bocytopenic	purpura	(ITP)	and	the	potential	to	identify	variants	 in	genes	known	to	
have	a	predisposition	to	hematological	malignancies,	it	could	become	a	critical	step	in	
improving	patient	clinical	management.
K E Y W O R D S
bleeding,	gene	mutations,	targeted	panel	sequencing,	thrombocytopenia
Essentials
•	 Inherited	thrombocytopenias	are	a	heterogeneous	group	of	disorders	with	over	30	causative	genes	identified	to	date.
•	 We	have	developed	an	IT-specific	gene	panel	to	screen	patients	using	the	rapid	Agilent	SureSelectQXT	transposon-based	enrichment	
system.
•	 Candidate	gene	variants	were	observed	in	previously	implicated	IT	genes	in	77%	of	individuals;	10%	of	patients	had	a	classified	
pathogenic	variant,	16%	had	a	likely	pathogenic	variant,	51%	had	a	variant	of	unknown	significance	and	23%	had	no	or	a	benign	
variant.
•	 Accurate	genetic	diagnosis	could	improve	the	clinical	outcome	for	this	group	of	patients	with	disproportionate	bleeding	for	their	re-
duced platelet count.
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Capture	 Enrichment	 and	 Agilent	 SureSelectQXT,	 both	 propose	 an	
improvement	in	sample	preparation	without	limitations	in	sequence	
depth,	coverage,	and	accuracy.10	When	applied	to	small-	scale	cus-
tom	gene	panels,	the	preparation	time	can	be	reduced	to	one	day.	In	
addition,	DNA	input	is	also	reduced	allowing	for	amplification	from	
<50	ng	of	DNA.11
Due	to	the	high	percentage	of	variants	within	known	IT	genes	as	
identified	by	whole	exome	sequencing	(WES)	in	a	previous	study,12 
and	 the	 increasing	 advances	 in	 custom	 panel	 next	 generation	 se-
quencing,	 an	 IT-	specific	 next-	generation	 sequencing	 (NGS)	 panel	
was	designed	and	included	within	the	UK-	GAPP	patient	workflow.	
Incorporating	a	small	custom	panel	prior	to	WES	has	the	potential	to	
filter	out	variants	with	a	genetic	etiology	of	disease	within	known	IT-	
causing	genes.	Coupled	with	the	Agilent	SureSelectQXT	transposon-	
based	 system	of	 sample	preparation,	 an	 increase	 in	 the	efficiency	
of	genetic	diagnosis,	as	well	as	a	reduction	 in	the	overall	cost,	can	
potentially be achieved.
Therefore,	in	this	study	we	aimed	to	implement	a	NGS	panel	in	
the	UK-	GAPP	patient	workflow.	The	panel	was	designed	 to	 incor-
porate	all	genes	known	to	be	previously	associated	with	 IT,	effec-
tively	pre-	screening	patients	before	WES.	The	targeted	panel	also	
takes	advantage	of	 a	 rapid	 sample	preparation	 technique	allowing	
for	 quick	 genetic	 diagnosis	 following	patient	 phenotyping	 and	 im-
proving	overall	diagnosis	of	recruited	patients.
2  | METHODS
2.1 | Patients
Patients	were	recruited	from	participating	UK	hematology	centers.	
All	 patients	had	a	bleeding	history	 taken	at	 the	point	of	 examina-
tion	and	inclusion	into	the	study.	Most	patients	suffered	from	mild	
bleeding	 symptoms	 including	 cutaneous	 bruising,	 bleeding,	 and	
epistaxis	 in	 addition	 to	 more	 severe	 bleeding	 symptoms	 in	 some	
cases.	Detailed	 patient	 clinical	 symptoms	 related	 to	 bleeding	 that	
were	available	are	displayed	in	Table	1.
The	UK-	GAPP	study	was	approved	by	the	National	Research	Ethics	
Service	Committee	of	West	Midlands—Edgbaston	(06/MRE07/36)	and	
participants	 gave	 written	 informed	 consent	 in	 accordance	 with	 the	
Declaration	of	Helsinki.	The	GAPP	study	was	registered	at	www.isrctn.
org	 as	 #ISRCTN	77951167	 and	 is	 included	 in	 the	National	 Institute	
of	 Health	 Research	 Non-	Malignant	 Haematology	 study	 portfolio,	
(ID-	9858).
2.2 | Platelet counts and morphology
Platelet	 counts	 and	 morphology	 were	 measured	 from	 patients	 in	
whole	blood	using	 the	Sysmex	XN-	1000	 (n	=	31).	The	PLT-	F	chan-
nel	was	used	to	determine	platelet	counts	 in	whole	blood	and	the	
immature	platelet	 fraction	 (IPF).	Mean	platelet	 volume	 (MPV)	was	
determined	 from	 the	 impedance	 PLT-	I	 channel.	 All	 samples	 were	
processed	in	tandem	with	travel	controls.
2.3 | Platelet preparation and platelet 
function testing
This	study	focuses	on	a	subset	of	patients	with	a	reduction	in	plate-
let	count.	Previous	studies	by	the	UK-	GAPP	study	group	have	dem-
onstrated	the	applicability	of	using	light	transmission	aggregometry	
(LTA),	including	lumiaggregometry,	for	investigation	of	PRP	samples	
having	platelet	counts	exceeding	1	×	108/mL13	and	an	in-	house	flow-	
cytometry	assay	to	assess	platelet	function	in	patients	having	plate-
let	counts	in	PRP	of	less	than	1	×	108/mL.12
2.4 | Thrombocytopenia- specific panel sequencing
A	thrombocytopenia	panel	was	designed	 for	use	as	an	 initial	NGS	
(NGS)	 sequencing/pre-	screen	 before	 whole	 exome	 sequencing	 in	
collaboration	with	the	Regional	Genetics	laboratory	at	Birmingham	
Women’s	Hospital.
The	 panel	 was	 designed	 using	 the	 Agilent	 SureDesign	 v3.5.4	
(Agilent	 Technologies,	 UK)	 design	 software.	 The	 original	 design	
included	 the	 following	 30	 genes;	 ABCG5,	 ABCG8,	 ADAMTS13,	
ANKRD18A,	ANKRD26,	CYCS,	FLI1,	FLNA,	FYB,	GATA1,	GFI1B,	GP1BA,	
GP1BB,	 GP5,	 GP9,	 HOXA11,	 ITGA2B,	 ITGB3,	 MKL1,	 MPL,	 MYH10,	
MYH9,	NBEAL2,	ORAI1,	RBM8A,	RUNX1,	SLFN14,	STIM1,	TUBB1,	and	
WAS.	The	30	genes	encompassed	genes	previously	associated	with	
IT	as	well	as	some	of	their	related	genes	and	novel	genes	identified	as	
being	associated	with	thrombocytopenia	as	part	of	the	GAPP	study.	
This	panel	was	applied	to	patients	48	to	61	(inclusive)	and	patients	
72	 and	73,	which	 encompass	 the	 first	 16	 patients	 that	were	 ana-
lyzed	by	panel	sequencing.	Sequencing	probes/baits	were	designed	
to	cover	the	following	regions:	all	coding	exons	±10	bp	flanking	se-
quence	from	the	intron-	exon	boundary	and	the	5′UTR	and	3′UTR.	
Sequencing	baits	were	designed	with	2x	density	so	that	each	desired	
region	was	covered	by	at	least	two	overlapping	probes.	Baits	were	
also	 designed	 with	 the	 strictest	 masking	 stringency	 settings	 pos-
sible.	 SureDesign	masks	 repetitive	 sequences	dependent	on	 three	
masking	 tools:	RepeatMasker,	WindowMasker,	and	Uniqueness	35	
track.	The	design	software	uses	combinations	of	all	 three	 tools	 to	
create	three	masking	stringencies	which	vary	in	their	inclusiveness	
of	 repeat	 regions.	 If	baits	 could	not	be	 found	 in	 the	highest	 strin-
gency	possible,	stringency	was	decreased	until	they	could	be	found.	
Eighteen	genes	were	covered	entirely	using	the	highest	stringency	
setting,	 eight	 genes	 were	 covered	 by	 a	 combination	 of	 high	 and	
moderate	 stringency	 settings,	 and	 the	 remaining	 four	 genes	were	
covered	by	baits	using	a	combination	of	all	three	stringency	settings.	
Balanced	boosting	of	GC-	rich	probes	was	used	which	replicated	the	
amount	of	probes	within	a	GC-	rich	region	by	a	defined	factor	to	im-
prove	capture	of	these	difficult	genomic	fragments.	The	final	design	
incorporated	3309	probes	with	an	overall	size	of	212.189	kbp.
For	subsequent	sequencing	beyond	the	first	group	of	16	patients	
as	detailed	above,	an	 improved	design	was	utilized	to	 include	new	
genes	 implicated	 in	 IT.	 The	 second	version	of	 the	design	 included	
all	probes	from	the	first	design	with	the	addition	of	baits	designed	
to	sequence	the	following	genes;	ACTN1,	ETV6,	PF4,	and	PRKACG. 
4  |     JOHNSON et al.
TABLE  1 Phenotypic	symptoms	of	31	patients	recruited	to	the	UK-	GAPP	study	with	IT	of	unknown	etiology
Patient Age Gender
Platelet 
count 
(x109/l) MPV (fL) IPF (%)
Flow 
cytometry 
defect LTA defect
ATP 
secretion Bleeding phenotype
48 5 M 125 9.1 NT P-	Selectin NT NT Cutaneous	bruising,	petechiae
49 41 M 30 NA 9.4 NT ADP Normal Cutaneous	bruising
50 41 M 30 NA 59.4+ CD42b NT NT Cutaneous	bleeding
51 UNK UNK 162 9.2 NT P-	Selectin,	
GPVI
NT NT Cutaneous	bleeding,	oral	cavity	
bleeding
52 43 F 131 8.7 14.7+ Normal AA Reduced Cutaneous	bleeding,	epistaxis,	
menorrhagia,	Gi	bleeding,	oral	
cavity	bleeding
53 27 F 104 9.1 NT Fibrinogen NT NT Cutaneous	bleeding
54 12 M 101 10 39.8+ P-	Selectin NT NT Cutaneous	bleeding
55 UNK F 30 8.6 2.3 P-	Selectin NT NT Cutaneous	bruising,	oral	cavity	
bleeding,	menorrhagia
56 15 F 48 10.2 45.2+ Normal NT NT Cutaneous	bleeding,	epistaxis
57 11 F 153 12.1 9.2 NT ADP,	AA Reduced Cutaneous	bruising/bleeding
58 9 F 82 8.6 6.4 P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
59 4 M 94 12.3 7.1 Normal NT NT Cutaneous	bruising/bleeding
60 UNK F 146 13.4+ 15.8+ CD41 Adr Normal Cutaneous	bruising,	oral	cavity	
bleeding,	menorrhagia
61 UNK F 76 9.7 3.4 P-	Selectin,	
Fibrinogen
NT NT No	observable	phenotype
62 34 F 138 13.8+ 17.5+ Normal NT NT Cutaneous	bleeding
63 13 F 37 14.6+ 16+ P-	Selectin NT NT Cutaneous	bruising,	petechiae,	
epistaxis
64 UNK F 105 14.5+ 23.1+ NT Normal Normal Cutaneous	bruising,	epistaxis
65 35 F 52 14.9+ 19.4+ P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
66 18 F 87 10 1.8 P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
67 22 M 40 13.1+ 15.7+ NT Normal Normal Cutaneous	bruising/bleeding,	
epistaxis
68 17 M 191 NT NT NT NT NT Cutaneous	bleeding,	nose	
bleeds
69 26 M 69 NT NT NT NT NT Nose	bleeds
70 34 F 96 NT NT NT NT NT None,	incidentally	identified	
thrombocytopenia
71 50 M 128 NT NT NT NT NT None,	investigated	as	son	has	
thrombocytopenia
72 33 F 14 NT NT NT NT NT Cutaneous	bleeding,	menorrha-
gia,	acute	lymphoblastic	
leukemia,	father	died	of	acute	
myeloid	leukemia
73 29 F 53 11.7 9.1 NT NT NT Cutaneous	bruising,	hematuria,	
oral	cavity	bleeding
74 72 M 50 8.4 NT P-	Selectin NT NT Cutaneous	bruising,	epistaxis
75 48 F 92 NT NT NT NT NT Cutaneous	bruising,	hematomas
76 UNK F 92 10.2 NT Fibrinogen NT NT No	observable	phenotype
(Continued)
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All	genes,	with	the	exception	of	PRKACG,	were	covered	by	probes	
with	the	most	stringent	masking	settings.	Probes	designed	for	am-
plification	and	sequencing	of	PRKACG	included	four	probes	with	the	
least-	stringent	masking	settings	applied.	Overall	the	new	design	in-
corporated	3447	probes	covering	221.305	kbp.	Target	enrichment	
was	performed	for	all	designs	using	the	Agilent	SureSelectQXT	NGS	
target	 enrichment	 kit	 for	 Illumina	multiplexed	 sequencing	 (Agilent	
Technologies).	Sample	preparation	followed	the	workflow	outlined	
in	 the	 manufacturer’s	 instructions	 (Figure	1).	 Due	 to	 the	 relative	
small	 size	of	 the	capture	 library	all	 size-	related	steps	 followed	 the	
methodology	for	capture	libraries	<3	Mb.	In	the	preparation	for	hy-
bridization	750	ng	of	gDNA,	diluted	in	a	volume	of	12	μL	was	used.
A	maximum	of	16	samples	were	prepared	per	run.	DNA	samples	
were	quantified	using	BR	and	High	Sensitivity	 (HS)	Qubit	dsDNA	
fluorometric	quantification	kits	and	were	analyzed	using	a	Qubit	
2.0	Fluorimeter	(ThermoFisher,	UK,	#Q32854	for	HS	kit)	in	initial	
sample	preparation.	Purification	steps	utilized	Agencourt	AMPure	
XP	magnetic	capture	beads	(BeckmanCoulter,	UK,	#A63880).	DNA	
quantity	and	quality	was	assessed	at	two	separate	points	through-
out	 the	 protocol	 using	 an	 Agilent	 2200	 Tapestation	 system	 and	
associated	D1000	and	high	sensitivity	D1000	screen	tape	(#5067-	
5582	for	D1000,	#5067-	5584	for	HS	D1000),	and	reagents	(includ-
ing	 ladder	and	sample	buffers)	 (#5067-	5583	for	D1000	reagents,	
#5067-	5585	 for	 HS	 D1000	 reagents)	 (Agilent	 Technologies).	
Dynabeads	MyOne	Streptavidin	T1	magnetic	beads	were	used	for	
hybrid	 capture	 (ThermoFisher,	 #65601).	 Index	 tags	 were	 added	
using	the	SureSelectQXT	P7	and	P5	dual	indexing	primers.	All	ther-
mocycling	 steps	 were	 performed	 using	 a	 Bio-	Rad	 DNA	 Engine	
Tetrad	2	Thermal	Cycler	 (Bio-	Rad,	UK).	Magnetic	 separation	was	
achieved	using	a	DynaMag-	96	Side	magnet	(ThermoFisher).
Samples	were	 then	pooled	 for	multiplexed	 sequencing	 so	 that	
each	 index-	tagged	 sample	was	 in	 equimolar	 amounts	 in	 the	 pool.	
For	each	sample	the	following	formula	was	used	to	determine	the	
amount	of	index	sample	to	use.
where V	(f)	=	Final	desired	volume	of	pool;	C	(f)	=	Desired	final	con-
centration	of	all	DNA	 in	pool;	#	=	is	 the	number	of	 the	 indexes;	C 
(i)	=	Initial	concentration	of	each	sample.
A	final	desired	volume	of	pool	of	20	μL	was	used	and	a	final	con-
centration	of	4	nmol/L.	In	all	cases	16	indexes	were	pooled.
To	achieve	an	optimal	cluster	density,	a	final	concentration	
of	 10-	pmol/L	 DNA	 was	 used.	 DNA	 was	 firstly	 denatured	 by	
the	 addition	 of	 5	μL	 of	 0.2	mol/L	 NaOH	 to	 5	μL	 of	 4	nmol/L	
pooled library and allowed to incubate at room temperature 
(~20°C)	for	5	minutes	before	adding	990	μL	of	pre-	chilled	HT1	
hybridization	 buffer	was	 added	 to	 achieve	 a	 20-	pmol/L	 solu-
tion. A 300- μL	 aliquot	 of	 the	20-	pmol/L	 solution	was	diluted	
with 300 μL	HT1	to	achieve	a	final	concentration	of	10	pmol/L	
in 600 μL.
Finally	 sequencing	 was	 performed	 using	 an	 Illumina	 MiSeq	
(Illumina,	 UK)	 and	 MiSeq	 v2	 300	 Cycle	 Reagent	 Kits	 (Illumina,	
#15033626).	 Sample	 sheets	were	designed	 to	 allow	 for	 the	use	of	
custom	 primers	 and	 no	 adaptor	 trimming.	 Sequencing	 followed	 a	
Nextera	XT	sample	preparation	kit	and	amplicon	chemistry.
Sequence	 alignment,	 annotation,	 categorisation	 and	 variant	
calling	 was	 performed	 using	 the	 SureCall	 v3.5	 software	 (Agilent	
Technologies)	 and	 the	 GenAligners	 3.0	 alignment	 tool	 (Agilent	
Technologies).	 Post	 aligned,	 annotated,	 and	 categorized	 sequence	
data	was	analyzed	using	a	personalized	bioinformatics	pipeline	as	dis-
cussed	below.
2.5 | Bioinformatics pipeline to determine 
candidate variants
Sequence	data	generated	using	the	IT-	specific	NGS	panel	was	ana-
lyzed	using	an	adaptation	of	the	pipeline	developed	for	the	analysis	
of	WES	data.12	Variants	were	initially	filtered	on	frequency,	exclud-
ing	variants	with	a	MAF	≤0.01	in	the	1000-	G	database.	Synonymous	
variants	 not	 predicted	 to	 change	 the	 amino	 acid	 sequence	 in	 the	
protein	 coding	 transcripts	were	 then	 excluded.	 As	 the	 panel	 was	
designed	to	include	the	5′	and	3′	UTRs,	variants	were	additionally	
Volume of Index=
V(f)×C(f)
#×C(i)
Patient Age Gender
Platelet 
count 
(x109/l) MPV (fL) IPF (%)
Flow 
cytometry 
defect LTA defect
ATP 
secretion Bleeding phenotype
77 15 F 76 9.4 13.5+ Normal NT NT Oral	cavity	bleeding,	
menorrhagia
78 UNK M 101 13.9+ 14.4+ Normal Adr Normal Cutaneous	bleeding
Average	platelet	count	=	88	×	109/L	(normal	range	to	2	SD	147-	327	×	109/L,	n	=	40).	Average	MPV	=	11.1	fL	(mean	normal	range	to	2	SD	7.8-	12.69	fL,	
n	=	40).	IPF	was	available	for	20	patients	and	varied	between	1.8-	59.4%	(normal	range	1.3-	10.8%,	n	=	40).	Patients	with	an	observed	macro	and	micro	
thrombocytopenia	are	denoted	by	a	+	and	-	,	respectively,	following	their	most	recent	analyzed	MPV.	Secondary	qualitative	defects	are	abbreviated	to	
the	following;	(CD41)	reduction	in	the	resting	cell	surface	levels	of	CD41,	(CD42b)	reduction	in	resting	cell	surface	levels	of	CD42b,	(ADP)	reduction	in	
response	upon	ADP	 stimulation	 indicating	 a	 possible	 defect	 in	 the	Gi	 pathway,	 (AA)	 reduction	 (cyclooxygenase	pathway	defect),	 (Adr)	 reduction	
(Thromboxane	receptor	pathway	defect),	(GPVI)	reduction	in	surface	GPVI	quantity,	(P-	selectin)	reduction	(platelet	alpha-	granule/secretion	defect),	
(fibrinogen)	reduction	in	the	binding	of	fibrinogen	to	activated	platelets,	(ATP	secretion)	reduction	in	ATP	secretion	upon	stimulation	with	PAR-	1	pep-
tide 100 μmol/L.	Bleeding	diathesis	of	each	individual	is	summarized	under	bleeding	phenotype.
AA,	arachadonic	acid;	ADP,	Adenosine	diphosphate;	Adr,	adrenaline;	ATP,	Adenosine	triphosphate;	GPVI,	Glycoprotein	VI;	IPF,	immature	platelet	frac-
tion;	LTA,	light	transmission	aggregometry;	MPV,	mean	platelet	volume.	+	denotes	an	elevated	MPV/IPF;	NA	indicates	parameter	was	tested	but	results	
were	inconclusive;	NT	indicates	parameter	was	not	tested	due	to	degraded	or	limited	sample;	UNK	indicates	the	parameter	was	not	known.
TABLE  1  (Continued)
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filtered	dependent	on	their	genomic	location	within	the	coding	re-
gion	 ±10	bp	 of	 intron-	exon	 boundaries.	 The	 UTRs	 were	 included	
in	bait	 design	 to	 allow	detection	of	 variants	within	 the	5′	UTR	of	
ANKRD26	so	that	all	variants	occurring	within	the	5′UTR	of	genes	
were	analyzed	individually.	Candidate	variants	identified	were	scru-
tinized	 using	 the	 same	 in	 silico	 pathogenicity	 prediction	 software	
and	variant	classification	system	as	candidates	from	WES	analysis	
as	outlined	previously.12	Finally,	pathogenicity	of	variants	was	de-
termined	 and	 called	 using	 the	 consensus	 guidelines	 as	 set	 out	 by	
the	American	College	of	Medical	Genetics	and	Genomics	and	 the	
Association	for	Molecular	Pathology	(hence	forth	referred	to	as	the	
ACMG	guidelines).14
2.6 | Quality of sequence data, average number of 
variants, and sequence coverage
All	 individual	 DNA	 samples	were	 processed	 and	 passed	QC	 at	
two	 points	 during	 sample	 preparation.	 Prior	 to	 sample	 pooling	
an	average	calibrated	DNA	concentration	of	2.957	ng/μL	and	a	
molarity	of	13.3	nmol/L	was	observed	across	all	samples.	All	se-
quencing	 runs	passed	 internal	QC	that	 is	used	within	 the	West	
Midlands	Regional	Genetics	Service	at	the	Birmingham	Women’s	
Hospital	 and	 internal	 QC	 from	 the	 SureCall	 analysis	 software.	
All	 candidate	 variants	 identified	were	 classified	 as	 high	quality	
mapped	variants	with	a	quality	score	of	255	using	the	SureCall	
software.
3  | RESULTS
3.1 | Phenotyping of IT patient cohort recruited to 
the study
All	 31	 unrelated	 cases	 included	 in	 this	 study	 underwent	 clinical	
evaluation	 to	 exclude	 idiopathic	 thrombocytopenic	 purpura	 (ITP)	
(following	a	relatively	stable	reduced	platelet	count	over	time)	and	
other	 nonplatelet	 disorders	 including	 von	Willebrand	 disease	 and	
inherited	coagulation	factor	deficiencies.	Subsequent	analysis	after	
enrolment	isolated	this	group	of	patients	with	a	suspected	platelet	
count	less	than	150	×	109/L	and	therefore	suspected	to	have	an	in-
herited	 thrombocytopenia	 of	 unknown	 etiology	 (Table	1).	 Platelet	
counts	 varied	 between	 30	 and	 162	×	109/L	 among	 the	 31	 indi-
viduals	with	a	mean	count	of	88	×	109/L	(Table	1)	 (normal	range	to	
two	 standard	 deviations	 147-	327	×	109/L,	 n	=	40).	 Patients	with	 a	
platelet	 count	 between	 150-	200	×	109/L	were	 retained	 for	 analy-
sis	within	 the	study	under	 the	stipulation	 that	 there	was	a	 shared	
phenotype	 within	 the	 patient	 and	 related	 affected	 family	 mem-
bers	 and	 that	 a	 prior	 platelet	 count	 has	 been	 below	 150	×	109/L.	
Mean	platelet	volumes	were	between	8.6-	14.6	fL	(n	=	23)	(mean	for	
healthy	controls	±2	SD	=	7.8-	12.4	fL).The	immature	platelet	fraction	
(IPF)	mean	in	the	patients	was	17%	of	the	total	platelet	count	(range	
1.8-	59.4%),	n	=	20	(normal	range	1.3-	10.8%,	n	=	40,	mean	4.4%),the	
higher	values	reflecting	abnormal	bone	marrow	platelet	production	
or	thrombopoiesis.
F I G U R E  1 Sample	preparation	
workflow	for	the	IT-	specific	next-	
generation	sequencing	panel	using	Agilent	
SureSelectQXT	capture	methodology
gDNA samples 1,2...n
Fragment DNA and
adaptor tag DNA ends in
single enzymatic step
Adaptor-tagged DNA library
PCR amplify
Prepared DNA library amplicons
Genomic locations of interest
Design target sequences in
SureDesign
SureSelect Capture Library
Hybridize using SureSelect Capture Library
Capture Library/prepared DNA library hybrids
Capture hybrids on streptavidin-coated
magnetic beads
Captured,target-enriched DNA library
PCR amplify using Dual
Indexing primers
Dual-indexed, target-enriched DNA library
Pool libraries for multiplex sequencing
SureSelect-enriched dual-indexed NGS samples
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LTA	was	used	 to	assess	platelet	 function	 for	 seven	patients	 and	
flow	cytometry	 alone	was	performed	 for	 samples	 from	17	patients.	
Platelets	 from	 individuals	 with	 a	 borderline	 platelet	 count	 in	 PRP	
of	 between	 0.1	 and	 0.15	×	109/L	were	 assessed	 using	 both	 assays	
(n	=	3).	Platelet	function	studies	revealed	the	suggestion	of	the	pres-
ence	of	a	secondary	qualitative	defect	in	addition	to	the	reduction	in	
platelet	count	in	19	of	24	(79%)	(Table	1)	of	the	overall	cohort	of	pa-
tients	tested.
3.2 | IT- specific NGS panel
On	average,	326	variants	were	noted	in	samples	from	each	individual	
analyzed	by	the	IT-	specific	NGS	panel.	This	ranged	from	265	to	400	
variants	across	all	samples	analyzed.	Following	exclusion	of	synon-
ymous	variants,	an	average	of	73	variants,	having	a	MAF	≤0.01	 in	
the	 1000-	G	 database	were	 noted	 per	 individual.	When	 the	 ExAC	
database	was	interrogated	for	each	of	the	variants	identified	in	non	
UTR	regions	only	those	variants	displayed	in	Table	3	were	of	a	rare	
frequency	(MAF	<0.01).
Average	coverage	across	the	targeted	regions	was	 in	excess	of	
95%	 for	 all	 samples	 analyzed.	 An	 average	 read	 depth	 of	 380	was	
noted	at	the	site	of	each	variation.	This	read	depth	was	not	observed	
below	121	at	each	point	of	all	candidate	variants	and	reached	a	fil-
tered	read	depth	of	823.
3.3 | Validation of IT- specific NGS panel
Validation	of	the	IT-	specific	NGS	panel	was	performed	by	ana-
lyzing	 the	 panel’s	 sensitivity	 in	 detecting	 eight	 variants	 iden-
tified	 previously	 by	 WES	 analysis	 and	 confirmed	 by	 Sanger	
sequencing.	 Variants,	 at	 the	 time	 of	 validation,	 were	 likely	
candidate	 variants	 and	 include	 variants	 in	 genes	 not	 known	
previously	 to	 cause	 IT	 (see	 Table	2).	 All	 variants,	 excluding	 a	
previously	 identified	 frameshift	 causing	 insertion	 in	 TUBB1; 
c.1080_1081insG,	p.Leu361Alafs*19	previously	identified	using	
WES	 in	 patient	 31,12	 were	 successfully	 identified,	 presum-
ably	due	 to	 the	 sequence	context	around	 this	genomic	 region.	
All	 known	 candidate	 variants	 tested	 were	 the	 only	 candidate	
variants	 following	 bioinformatics	 analysis	 of	 panel	 sequencing	
results	in	each	patient.
3.4 | Candidate variants observed and variant 
prevalence in 31 new patients
In	total,	DNA	samples	from	31	new	patients	were	analyzed	by	an	
IT-	specific	NGS	panel.	All	patients,	with	the	exception	of	64,	were	
single	affected	cases.	Patient	64	forms	part	of	a	pedigree	of	four	
affected	family	members	which	will	be	discussed	in	more	detail	in	
the	discussion	section.	Following	post-	sequencing	bioinformatics	
analysis	candidate	variants	previously	implicated	in	IT	genes	were	
observed	in	77%	of	individuals	(Table	3).	In	total,	37	variants	were	
noted	in	the	24	patients	observed	with	a	genetic	variant	in	a	gene	
previously	known	to	cause	IT.	Seven	patients	were	observed	with	
two	variants	in	two	different	genes	and	three	patients	were	noted	
to	have	three	variants.	No	patients	were	noted	with	two	variants	
occurring	within	the	same	gene	and	all	variants	were	observed	in	
a	heterozygous	state.	One	variant;	GP5;	c.867G>C,	p.Met289Ile,	
was	noted	in	two	unrelated	patients,	57	and	58.
The	majority	of	variants	identified	were	missense	variants	affecting	
a	single	amino	acid.	This	equated	to	89%	of	the	variants	observed.	In	ad-
dition;	one	5′UTR	start	gain	was	noted	in	patient	48	(TUBB1;	c.-	88G>C),	
one	 frameshift	 causing	 deletion	 was	 noted	 in	 patient	 50	 (GP1BB; 
c.del120-	142,	p.Arg42Cys	fs*14),	one	stop	loss	variant	was	noted	in	pa-
tient	54	(GATA1;	c.1240T>C,	p.*414Arg+41),	and	one	nonsense	causing	
SNV	was	observed	in	patient	60	(ITGA2B;	c.2176A>T,	p.Lys726*).
Of	the	37	variants,	11	(30%)	were	novel	and	not	previously	iden-
tified	in	any	of	the	databases	scrutinized.	Twenty-	six	variants	have	
been	observed	previously	 and	 the	prevalence	of	 these	 variants	 in	
the	ExAC	database,	unless	otherwise	stated,	is	displayed	in	Table	3.	
When	comparing	all	previously	observed	variants	an	average	MAF	
of	0.00256	 is	noted.	All	variants	were	observed	at	a	 frequency	of	
less	than	0.01	and	all	previously	identified	variants,	with	the	excep-
tion	 of	 rs111527738	which	was	 present	within	 the	 latest	 build	 of	
dbSNP.	Four	pathogenic	or	 likely	pathogenic	 variants	were	 identi-
fied	that	are	previously	known	to	cause	IT.	These	were	found	in	pa-
tients;	54	(GATA1;	c.1240T>C,	p.*414Arg+41),	59	(RUNX1;	c.386C>A,	
Patient Gene Variation Type
2 ANKRD26 c.-	126T>G 5′-	UTR
17 RUNX1 c.G236A,	pTrp79* Nonsense
20 RUNX1 c.G332A,	p.Gly108Ser Partial	heterozy-
gous	missense
21 RUNX1 c.427	+	1G>T Splice	site	variant
26 SLFN14 c.A652G,	p.Lys218Glu Missense
31 TUBB1 c.1080_1081insG,	
p.Leu361Alafs*19
Frameshift	causing	
insertion
36 WAS c.G1456A,	p.Glu486Lys X-	linked	Missense
41 ANKRD18A c.2395_2397del,	p.Glu799del Non-	frameshift	
causing	deletion
TABLE  2 Eight	patients	and	the	eight	
known	candidate	variants12	representing	a	
range	of	mutation	types	utilized	for	the	
validation	of	the	IT-	specific	next-	
generation	sequencing	panel
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p.Ala129Glu),	 70	 (GFI1B;	 c.503G>T,	 p.Cys168Phe),	 and	 64	 (MYH9; 
c.2152C>T,	p.Arg718Trp).3,15–17
Patient	54,	a	12-	year-	old	male	with	a	history	of	cutaneous	bleed-
ing	and	a	mild	 reduction	 in	platelet	count	 (101	×	109/L)	was	noted	
with	 a	 stop	 loss	 variant	 in	GATA1;	 c.1240T>C,	 p.*414Arg+41.	 The	
predicted	effect	of	variation	is	a	loss	of	the	wild	type	stop	codon	and	
extension	of	the	protein	by	41	amino	acids.	Most	reported	variants	
within GATA1	occur	within	the	N-	terminal	zinc	finger	domain,	lead-
ing	to	a	disruption	of	the	binding	of	GATA1	to	FOG1.	The	stop-	loss	
variant	noted	in	patient	54,	was	first	identified	in	a	67-	year-	old	male	
proband	 who	 suffers	 from	 easy	 bruising.16	 The	 patient’s	 platelet	
counts	varied	between	86	to	94	×	109/L	at	different	times	of	testing	
and	no	other	differences	in	hematological	cell	numbers	were	noted.	
The	patient	was	initially	sequenced	due	to	the	presence	of	a	rare	X-	
linked	blood	group	Lu(a-	b-	)	phenotype	which	results	in	the	marked	
decrease	in	expression	of	Lutheran	glycoprotein	on	the	erythrocyte	
cell	 surface.	 To	 date,	 serological	 analysis	 using	 flow	 cytometry	 to	
analyze	 the	 presence	 of	 Lutheran	 on	 the	 erythrocyte	 cell	 surface	
has	not	been	undertaken	 in	patient	54.	Also	the	presence	of	giant	
occasional	macrothrombocytes,	 a	marker	of	 the	published	pheno-
type,	have	not	been	observed	 in	patient	54	 in	 routine	histological	
examination.
A	previously	 identified	 causative	 variant	was	noted	 in	RUNX1 
in	 patient	 59.	 The	missense	 variant,	 c.386C>A,	 p.Ala129Glu,	was	
found	in	addition	to	a	missense	variant	in	ITGA2B.	The	variant	has	
previously	been	reported	to	be	causative	of	FPD/AML	in	three	pa-
tients	 from	a	 single	pedigree.15	All	 three	patients	were	 identified	
with	 the	 p.Ala129Glu	 germline	 mutation	 causative	 of	 FPD/AML.	
All	 patients	 developed	 AML	 as	 a	 result	 of	 a	 secondary	 somatic	
event	 occurring	within	RUNX1	 progressing	 to	 patient	 death	 in	 all	
cases.	Patient	59	 is	a	male	with	a	mild	reduction	 in	platelet	count	
to	94	×	109/L.	 Following	platelet	 function	 testing	 no	 reduction	 in	
platelet	secretion	(a	hallmark	of	variants	within	RUNX1)	was	noted.	
However,	 it	 is	highly	 likely	 that	 the	variant	observed	 in	RUNX1	 is	
causative	 of	 the	 hemostatic	 phenotype	 observed.	 Whether	 the	
variant within ITGA2B	 is	 additive	 to	 the	 phenotype	 is	 unlikely	 as	
the	platelet	 count	 is	 considered	mild	 in	 severity	but	may	warrant	
further	investigation.
Patient	64,	is	the	only	patient	analyzed	by	the	IT-	specific	panel	
for	whom	affected	family	members	were	also	recruited	to	the	study.	
The	patient	forms	part	of	a	pedigree	of	four	affected	family	members	
with	a	shared	phenotype	and	clinical	symptoms.	Following	analysis	
of	 the	 IT-	specific	panel	sequencing,	a	missense	variant	was	 identi-
fied	in	MYH9;	c.2152C>T,	p.Arg718Trp.	This	variant	has	been	noted	
once	previously	in	a	patient	initially	diagnosed	with	MYH9-	RD.3	The	
variant	occurs	within	the	motor	domain	of	MYH9	and	is	associated	
with	an	 increased	risk	of	deafness	and	nephritis,	however,	no	sec-
ondary	 symptoms	have	previously	 been	 reported	 in	 patient	64	or	
any	of	the	affected	family	members	also	recruited	to	the	UK-	GAPP	
study.	However	patients	such	as	this	should	be	monitored	regularly	
for	 signs	 of	 kidney	 disease.	 Two	 variants	 previously	 identified	 by	
WES	analysis	of	69	patients	were	also	identified	in	patients	analyzed	
by	the	IT-	specific	panel	sequencing.	These	variants;	CYCS;	c.155C>T,	
p.Ala52Val,	and	ITGA2B;	c.2176A>T,	p.Lys726*	were	identified	in	pa-
tients	50	and	60,	respectively.
3.5 | Conservation, pathogenicity prediction, and 
variant classification
Conservation	 at	 the	 site	 of	 variation	was	 determined	 by	 PhyloP	
and	PhastCons	in	silico	software.	Conservation	scores	for	all	vari-
ants	occurring	within	known	 IT-	causing	genes	 in	 the	31	patients	
are	 shown	 in	 Table	3.	 Average	 scores	 of	 3.32887	 and	 0.829571	
were	observed	across	all	variants	in	PhyloP	and	PhastCon	analy-
sis,	respectively.	The	majority	of	variants	occurred	at	sites	of	high	
conservation	and	the	two	methodologies	used	were	in	agreement	
in	all	instances.
Pathogenicity	was	predicted	using	 in	silico	prediction	software	
as	displayed	in	Table	3.	Classification	often	varied	amongst	the	soft-
ware	 used	 for	 each	 variant	 indicating	 the	 benign	 potential	 of	 the	
variants	observed.
In	total,	of	the	37	total	variants	noted	across	all	patients	investi-
gated,	three	variants	were	classified	as	“pathogenic”	and	five	“likely	
pathogenic”	when	considering	the	ACMG	consensus	guidelines.	The	
remaining	29	variants	without	a	positive	prediction	of	pathogenic-
ity	were	classified	as	of	“unknown	significance.”	Only	two	variants	
displayed	supporting	evidence	for	a	benign	classification.	Of	the	24	
patients	 where	 a	 genetic	 variant	 was	 identified	 this	 classification	
predicted	equated	 to	12%	 (3	of	24)	 of	 patients	with	 a	 pathogenic	
variant,	21%	(5	of	24)	with	a	likely	pathogenic	variant,	and	67%	(16	of	
24)	variants	of	unknown	significance.
4  | DISCUSSION
An	IT	gene–specific	NGS	panel	was	developed	in	order	to	pre-	screen	
patients	prior	to	WES.	The	aim	was	to	filter	out	patients	with	vari-
ants	in	known	IT-	causing	genes	allowing	subsequent	focus	on	WES	
for	patients	who	may	harbor	variants	in	novel	genes.	In	addition,	the	
cost	 implications	 were	 an	 important	 consideration	 given	 that	 the	
WES	was	more	than	four	times	as	expensive	compared	with	targeted	
panel	sequencing.
All	 sequencing	 passed	 QC	 at	 all	 points	 throughout	 sample	
preparation	and	QC,	 cluster	density	and	overall	 sequencing	data	
was	sufficient	when	compared	with	 routine	sequencing	using	al-
ternate	capture	methods	performed.	Although	considered	a	rapid	
capture	method,	 Agilent	 SureSelectQXT	 sample	 preparation	 does	
not	quite	reach	optimum	depth	of	coverage,	evenness	and	target	
enrichment	 when	 compared	 with	 alternate	 methods	 of	 capture	
including	 Agilent	 SureSelectXT.10,18	When	 applied	 to	 our	 custom	
designed	 panel,	 average	 coverage	 easily	 exceeded	 a	 universally	
accepted	 minimum	 20x	 coverage	 for	 efficiently	 calling	 variants	
and	an	average	read	depth	of	380	was	identified	at	the	points	of	
variation.19
With	a	GC	content	of	73%,	GP1BB	often	suffers	from	a	reduction	
in	 coverage,	which	 is	why	 in	WES	analysis	 the	gene	was	manually	
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TABLE  3 Variants	identified	by	analysis	of	the	IT-	specific	next-	generation	sequencing	pane
Patient Gene(s) Genomic variation Protein effect Variation type Prevalence PhyloP
48 ABCG5 c.293C>G p.Ala98Gly Missense 0.005	(rs145154937) 5.277
ABCG8 c.1667T>C p.Phe556Ser Missense 0.0009	(rs548098742) 2.914
TUBB1 c.-	88G>C 5′UTR	start	gain 0.004	(1000G)	(rs150072434)
49 ABCG5 c.1864A>G p.Met622Val Missense 0.00541	(rs140374206) −0.748
NBEAL2 c.6631G>A p.Asp2211Asn Missense Novel 5.515
50 CYCS c.155C>T p.Ala52Val Missense Novel 5.962
GP1BB c.del120- 142 p.Arg42Cys	fs*14 Frameshift	deletion Novel
51 FLI1 c.812G>A p.Arg271Gln Missense Novel 5.983
MYH9 c.2872G>A p.Ala958Thr Missense 0.0009	(rs151036570) 6.088
52 FLNA c.5948C>T p.Ser1983Leu Missense 0.0026	(rs187029309) 5.952
53 FLNA c.7583A>T p.Asp2528Val Missense Novel 4.858
MYH9 c.7C>G p.Gln3Glu Missense 0.0015	(rs56200894) 4.643
TUBB1 c.1199G>A p.Ser400Asn Missense Novel 5.88
54 GATA1 c.1240T>C p.*414Arg+41 Stop	loss Known 2.408
55 GP1BA c.206C>T p.Pro69Leu Missense 0.001872	(rs138825640) −1.407
56 GP1BB c.242T>G p.Leu81Arg Missense Novel −0.162
57 GP5 c.867G>C p.Met289Ile Missense 0.003101	(rs142440028) 2.516
58 GP5 c.867G>C p.Met289Ile Missense 0.003101	(rs142440028) 2.516
STIM1 c.182A>G p.Glu61Gly Missense 0.00004941	(rs202160755) 2.851
59 ITGA2B c.886G>A p.Gly296Arg Missense Novel 3.205
RUNX1 c.386C>A p.Ala129Glu Missense Known	(rs267607026) 6.077
60 ITGA2B c.2176A>T p.Lys726* Nonsense Novel 1.419
61 ITGA2B c.2417G>A p.Ser806Asn Missense Novel 0.148
WAS c.995T>C p.Val332Ala Missense 0.0051	(rs2737799) 0.096
62 MKL1 c.569C>T p.Pro190Leu Missense 0.00016	(rs200309955) 3.693
63 MKL1 c.1492G>C p.Val498Leu Missense 0.000008638	(rs199750225) 2.138
64 MYH9 c.2152C>T p.Arg718Trp Missense Known 2.044
65 MYH9 c.5074G>A p.Ala1692Thr Missense Novel 4.087
66 MYH10 c.2987C>T p.Ala965Val Missense 0.0079 4.822
NBEAL2 c.4361C>T p.Thr1454Met Missense 0.0001 3.227
67 TUBB1 c.421G>A p.Gly141Arg Missense 0.00003295	(rs778975827) 5.803
68 ABCG8 c.1629G>T p.Arg543Ser Missense 0.0002	(rs201690654) 5.057
69 ACTN1 c.136C>T p.Arg46Trp Missense 0.00000827 5.532
70 GFI1B c.503G>T p.Cys168Phe Missense 0.0006011	(rs527297896) 4.334
71 RUNX1 c.86T>C p.Leu29Ser Missense 0.01629	(rs111527738) 0.683
NBEAL2 c.4085G>A p.Arg1362Gln Missense 0.00000829 1.666
GFI1B c.551G>C p.Arg184Pro Missense 0.00000746 1.433
72–78 Unknown
(Continued)
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Patient Phastcons Mutation taster PolyPhen- 2 SIFT Provean ACMG criteria Classification
48 1 D D D D PP3 Uncertain	significance
1 D D D D PP3 Uncertain	significance
Uncertain	significance
49 0 P B T N BP4 Uncertain	significance
0.997 D D D D PM2,	PP3 Uncertain	significance
50 1 D B D D PM2 Uncertain	significance
D PM2,	PP3,	PM4,	PP4 Likely	pathogenic
51 1 D D D D PM2,	PP3 Uncertain	significance
1 D B T N Uncertain	significance
52 1 P D D D Uncertain	significance
53 1 D D D D PM2,	PP3, Uncertain	significance
0.998 D B D N Uncertain	significance
0.972 D B D N PM2 Uncertain	significance
54 0.572 P PM4,	PS1,	PP5 Likely	pathogenic
55 0 P B D D Uncertain	significance
56 0.175 P D D D PM2,	PP4 Uncertain	significance
57 0.55 P B D D Uncertain	significance
58 0.55 P B D D Uncertain	significance
1 D B D D Uncertain	significance
59 0.999 D B D D PM2 Uncertain	significance
1 D D D D PP3,	PS1,	PS3 Pathogenic
60 0.957 D PM2,	PM4,	PVS1,	PP4 Pathogenic
61 0.286 P B T N PM2 Uncertain	significance
0 P B T N BP4 Uncertain	significance
62 0.987 D B T D Uncertain	significance
63 0.998 D B T N Uncertain	significance
64 1 D D D D PP3,	PS1,	PS3,	PM	
(segregation),	PP4
Pathogenic
65 1 D B T N PM2 Uncertain	significance
66 1 D B D D Uncertain	significance
0.999 D B T N Uncertain	significance
67 1 D D D D PP3 Uncertain	significance
68 1 D D D N PM2 Uncertain	significance
69 1 D D D D PS1,	PM2,	PP3 Likely	pathogenic
70 1 D D D D PS1,	PM2,	PP3 Likely	pathogenic
71 1 P D T N Uncertain	significance
1 P D T N Uncertain	significance
0.995 D D D D PS1,	PM2,	PP3 Likely	pathogenic
72–78 N/A
Prevalence	is	shown	in	the	ExAC	consortium	if	not	specified	otherwise.	PhyloP	and	Phastcons	scores	are	shown.	Variants	are	noted	as	D,	disease	
causing	and	P,	polymorphism	in	MutationTaster;	D,	damaging	and	T,	tolerated	in	SIFT;	D,	deleterious	and	N,	neutral	in	Provean;	D,	damaging	and	
B,	benign	in	PolyPhen-	2	in	silico	pathogenicity	prediction	software.	PhyloP	scores	vary	between	−14	and	+6	and	measure	conservation	at	each	
individual	base,	sites	predicted	to	be	conserved	are	assigned	a	positive	score,	fast-	evolving	sites	are	assigned	a	negative	score.	Mutationtaster	
uses	a	Beyes	classifier	to	predict	the	effect	of	a	mutation	from	a	feed	a	classifiers.	SIFT	damaging	prediction	score	=	<0.05.	Provean	deleterious	
score	=	<	−2.5.	PolyPhen-	2	predictions	are	appraised	qualitatively	as	benign	or	damaging.	The	ACMG	consensus	guidelines,	including	supporting	
evidence,	are	also	shown.
TABLE  3  (Continued)
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analyzed.	 Utilizing	 the	 NGS	 panel	 there	 was	 no	 drop	 in	 coverage	
within GP1BB	for	all	patients	analyzed	and	two	variants,	in	patients	
50	and	56,	were	identified,	which	may	be	causative	of	disease.	This	
represents	variants	which	could	be	potentially	missed	by	other	se-
quencing	 methodologies	 and	 potential	 advantage	 of	 panel-	based	
sequencing.
In	 total,	 candidate	variants,	 that	could	be	considered	 for	 fur-
ther	analysis,	were	identified	in	77%	of	individuals	when	analyzed	
by	 the	 IT-	specific	 panel.	 This	 detection	 rate	 is	 in	 keeping	 with	
other	recent	previous	large-	scale	targeted	panel	sequencing	stud-
ies	and	the	application	of	WES	to	patients	with	IT	of	unknown	eti-
ology.4,12,20,21	One	possible	explanation	for	the	inflated	detection	
rate	for	panel	based	platforms	 is	the	relative	 increase	 in	average	
read	coverage	when	compared	to	WES	analysis,	especially	at	the	
point	of	variation.
When	comparing	prevalence,	however,	next-	generation	panel	se-
quencing	identifies	a	large	number	of	variants	that	have	been	previ-
ously	 identified	with	a	 low	MAF.	This	may	be	an	 indication	that	the	
variants	 are	 tolerated	 within	 the	 population	 and	 are	 not	 causative	
of	disease.	One	way	 to	determine	 this	would	be	 to	analyze	 the	co-	
segregation	 of	 variants	 within	 affected/unaffected	 relatives	 of	 the	
index	cases.	This	has	the	potential	to	rule	out	or	further	strengthen	
any	identified	variants	but	unfortunately	in	this	study	this	information	
was	unavailable.	The	most	comprehensive	database	of	genetic	vari-
ation	is	noted	to	be	the	ExAC	database,22	which	includes	data	from	
the	 aggregation	 and	 analysis	 of	 high-	quality	 exome	 sequence	 data	
for	60	706	individuals	of	diverse	ancestries	generated	as	part	of	the	
Exome	Aggregation	Consortium	(ExAC).	It	is	plausible,	therefore,	that	
although	the	variants	have	previously	been	noted,	they	are	causative	
of	a	mild	reduction	in	platelet	count	that	has,	or	has	not,	been	previ-
ously	diagnosed	in	all	other	patients	with	the	shared	variant.	To	de-
termine	the	reality	of	this	would	require	further	conformational	work.
Comparing	pathogenicity	prediction	and	variant	classification	to	
the	variants	determined	by	WES	analysis,	a	larger	percentage	of	vari-
ants	were	deemed	to	be	of	unknown	significance.	This	may	reflect	a	
reduced	rate	of	sensitivity	and	a	higher	proportion	of	false	negative	
variants	 identified.	 However,	 it	 is	 worth	 considering	 that	 the	ma-
jority	of	variants,	62%	(23	of	37),	displayed	supporting	evidence	of	
pathogenicity	but	lacked	sufficient	evidence	to	be	classified	as	such.	
This	could	potentially	be	an	indication	of	the	lack	of	strengthening	
evidence	 that	 is	normally	provided	 in	 the	 form	of	 related	affected	
family	members	that	would	be	recruited	to	the	study,	negatively	af-
fecting	classification	because	of	a	lack	of	segregation	analysis.
The	presence	of	a	variant	 in	MYH9	 in	patient	64	highlights	
the	 difficulty	 of	 picking	 up	 such	 defects	 despite	 the	 routine	
pre-	screening	 for	 disorders	 such	 as	 BSS-	 and	 MYH9-	related	
disease	 (using	 flow	cytometry	or	 the	presence	of	granulocyte	
inclusions,	 respectively)	 in	hemophilia	care	centers	before	 re-
cruitment	to	the	UK-	GAPP	study.	This	was	also	the	case	in	our	
previous	study	where	we	employed	WES	and	detected	MYH9	
and	BSS	defects	despite	pre-	screening	by	the	referring	labora-
tories.12	Analyzing	patients	using	the	IT-	specific	panel	has	eluci-
dated	variants	in	genes	known	to	cause	BSS-	and	MYH9-	related	
disease	 in	 seven	 patients.	With	 the	 exception	 of	 patients	 50	
and	 65,	who	 present	with	 the	 characteristic	 increase	 in	MPV	
to	 the	magnitude	of	observable	giant	platelets,	 the	 remaining	
patients	show	an	unaltered	MPV.	No	Döhle-	like	body	leukocyte	
inclusions	were	noted	on	peripheral	 blood	 smears	of	 patients	
64	and	65	and	no	patients	presented	with	secondary	symptoms	
relating	 to	 specific	 IT	 disorders.	 However	 it	 should	 be	 noted	
that	 not	 all	 MYH9	 defects	 are	 associated	 with	 the	 presence	
of	Dohle-	like	bodies	 in	 a	peripheral	blood	 smear.	The	defects	
identified	may	 therefore	be	 causative	of	non-	typical	 forms	of	
BSS-	and	MYH9-	related	IT	but	in	order	to	exclude	a	MYH9	de-
fect	 conclusively,	 immunofluorescence	 should	 be	 performed	
for	the	non-	muscle	myosin	heavy	chain	protein.
A	phenotype-	genotype	correlation	is	often	utilized	in	aiding	
in	the	diagnosis	of	a	patients	disease.	Patient	61	presented	with	
a	marked	reduction	in	the	cell	surface	levels	of	CD41,	the	inte-
grin	alpha	IIb,	 to	around	50%	of	the	 levels	observed	compared	
to	 the	 travel	control	 tested	simultaneously.	When	analyzed	by	
the	 IT-	specific	NGS	panel	 a	missense	 variant	was	 identified	 in	
ITGA2B.	This	variant,	c.2417G>A,	p.Ser806Asn,	 is	novel	within	
all	 databases	 but	 predicted	 benign	 and	 not	 well	 conserved	 at	
the	 site	 of	 variation.	 The	 variant	 occurs	within	 the	 extracellu-
lar	domain	and	the	integrin	alpha	IIb	heavy	chain.	Although	not	
predicted	to,	the	reduction	in	cell	surface	CD41	is	indicative	of	
the	possibility	that	the	variant	in	ITGA2B	affects	either	protein	
levels	or	cellular	localization	potentially	leading	to	the	observed	
platelet-	based	bleeding	phenotype.	This	is	the	only	occurrence	
of	a	genotype-	phenotype	correlation	in	all	patients	analyzed	by	
the	IT-	specific	NGS	panel.	Although	three	variants	were	identi-
fied	in	ITGA2B	and	one	variant	was	identified	in	GP1BA,	none	of	
the	patients,	with	 the	exception	of	61,	were	observed	 to	have	
a	reduction	in	the	corresponding	cell	surface	receptor	levels.
Interestingly	 a	 reduction	 in	 cell	 surface	 expression	 of	 CD42b,	
encoded by GP1BA,	was	noted	in	patient	50,	who	harbors	a	poten-
tially	deleterious	large	deletion	of	GP1BB	that	spans	two	previously	
reported	 disease-	causing	 variants.23,24	 Although	 not	 occurring	 in	
the	 encoded	 gene,	 the	 variant,	 due	 to	 the	 detrimental	 effect	 of	 a	
frameshift	causing	deletion,	may	have	propensity	to	disrupt	the	sta-
bility	of	the	receptor	complex	leading	to	a	reduction	in	cell	surface	
expression.
As	with	variants	determined	by	WES	analysis,	 the	variants	ob-
served	following	the	application	of	the	IT-	specific	NGS	panel	require	
further	 conformational	 work	 to	 be	 determined	 disease	 causing.	
Further	work	would	focus	around	this	point	mainly,	utilizing	many	of	
the	biomarkers	of	disease	attributed	to	variants	in	certain	genes	and	
recruiting	 related	affected	 family	members	of	previously	 analyzed	
patients.	This	will	strengthen	any	initial	genetic	variants	that	may	be	
indicative	of	disease	through	segregation	analysis	but	it	also	has	the	
propensity	to	spread	disease	awareness	of	an	under	recognized	and	
under-	diagnosed	genetic	disorder.
A	 possible	 lack	 of	 genotype–phenotype	 correlation	 shown	 in	
patients	 harboring	 variants	 in	 ITGA2B,	GP1BA,	 and	MYH9 in par-
ticular	 is	an	interesting	observation,	however,	further	work	would	
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be	needed	 to	validate	 this.	The	possibility	 that	 these	variants	are	
disease	causing	rests	on	the	functional	confirmation	of	the	effect	
of	variation.	However,	if	causative,	the	patients	represent	a	unique	
subset	 of	 each	 individual	 disease	 that	 does	 not	 share	 the	 typical	
phenotypic	presentation	of	previous	cases.	The	likelihood	that	pa-
tients	 exist	without	 the	 secondary	 symptoms	 and	 qualitative	 de-
fects	in	platelet	function	attributed	to	these	disorders	is	therefore	
relatively	high.
Seven	 patients	 in	 total	 were	 observed	 without	 any	 variants	 in	
genes	of	 the	 IT-	specific	panel.	The	sequencing	panel	employed	did	
not	look	at	Copy	Number	Variations	(CNVs)	which	could	be	present	in	
the	remaining	patients	studied.	Due	to	the	absence	of	variants	within	
the	panel	of	30	genes,	there	is	a	high	chance	that	the	genetic	etiology	
of	disease	is	due	to	variants	in	novel	genes	not	previously	implicated	
in	 IT.	Analysis	of	 these	patients	 in	particular	may	progress	our	cur-
rent	knowledge	of	 IT	through	the	determination	of	novel	causative	
genes.25
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